Published in Am J Med on May 01, 2008
Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia (2011) 1.27
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol (2010) 1.07
Serum cystatin C and prediabetes in non-obese US adults. Eur J Epidemiol (2013) 0.98
The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults. Diabetes Metab J (2016) 0.96
Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol (2012) 0.92
Cystatin C, cardiometabolic risk, and body composition in severely obese children. Pediatr Nephrol (2010) 0.91
Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol (2013) 0.81
Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome. Nutr Metab (Lond) (2011) 0.80
Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England. PLoS One (2015) 0.79
Impact of Growth Hormone on Cystatin C. Nephron Extra (2013) 0.76
Elevated circulating level of a cytokine, pancreatic-derived factor, is associated with metabolic syndrome components in a Chinese population. J Diabetes Investig (2015) 0.75
Relationship between High Serum Cystatin C Levels and the Risk of Gestational Diabetes Mellitus. PLoS One (2016) 0.75
Relationship between serum cystatin C and polycystic ovary syndrome. Iran J Reprod Med (2013) 0.75
Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses. PLoS One (2016) 0.75
Cystatin C, CRP, log TG/HDLc and metabolic syndrome are associated with microalbuminuria in hypertension. Arq Bras Cardiol (2013) 0.75
Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus. Vasc Health Risk Manag (2011) 0.75
Antidepressant Fluoxetine Modulates the In Vitro Inhibitory Activity of Buffalo Brain Cystatin: A Thermodynamic Study Using UV and Fluorescence Techniques. Biotechnol Res Int (2014) 0.75
The association between a low urine pH and the components of metabolic syndrome in the Korean population: Findings based on the 2010 Korea National health and nutrition examination survey. J Res Med Sci (2014) 0.75
Metabolic syndrome in IgA glomerulonephritis. Nephron Extra (2014) 0.75
Letter: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9). Diabetes Metab J (2016) 0.75
Response: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9). Diabetes Metab J (2016) 0.75
Association of body mass index, waist circumference, and metabolic syndrome with serum cystatin C in a Chinese population. Medicine (Baltimore) (2017) 0.75
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet (2010) 7.61
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS. J Am Coll Cardiol (2016) 2.32
Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med (2004) 2.18
High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis. J Am Coll Cardiol (2013) 2.15
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2010) 2.13
Intima-media thickness in severe obesity: links with BMI and metabolic status but not with systemic or adipose tissue inflammation. Diabetes Care (2013) 2.10
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab (2002) 1.98
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 1.92
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis (2005) 1.87
Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int (2004) 1.74
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab (2004) 1.70
Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med (2008) 1.66
Vaccination and chronic kidney disease. Nephrol Dial Transplant (2007) 1.63
Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant (2006) 1.61
Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med (2011) 1.61
Ear and kidney syndromes: molecular versus clinical approach. Kidney Int (2004) 1.59
A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther (2004) 1.53
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Renal safety of tenofovir in HIV treatment-experienced patients. AIDS (2004) 1.50
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis (2007) 1.49
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant (2005) 1.49
Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation (2002) 1.47
L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol (2012) 1.44
Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol (2009) 1.44
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int (2004) 1.43
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol (2008) 1.43
Intake of added oils and fats among middle-aged French adults: relationships with educational level and region of residence. J Am Diet Assoc (2005) 1.42
Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant (2003) 1.40
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation (2003) 1.40
Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant (2005) 1.40
Drug-induced Fanconi's syndrome. Am J Kidney Dis (2003) 1.38
Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas (2008) 1.31
Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med (2008) 1.31
Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs (2009) 1.26
Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis (2008) 1.25
Adiponutrin: A new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab (2004) 1.23
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Renal tubular drug transporters. Nephron Physiol (2006) 1.20
Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology (2002) 1.19
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther (2010) 1.18
Serum 25-hydroxyvitamin D concentration in subclinical carotid atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 1.18
Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. Eur Heart J (2009) 1.17
Herbs and the kidney. Am J Kidney Dis (2004) 1.16
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care (2007) 1.11
n-6 Fatty acids and cardiovascular health: a review of the evidence for dietary intake recommendations. Br J Nutr (2010) 1.09
Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant (2006) 1.08
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol (2013) 1.07
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics (2008) 1.06
Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol (2006) 1.06
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin Pharmacol Ther (2002) 1.06
Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol (2009) 1.04
Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol (2009) 1.03
Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract (2003) 1.03
Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS (2009) 1.01
Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol (2002) 1.01
Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis (2007) 1.01
Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit (2004) 1.00
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics (2005) 0.99
Renal tubular transporters and antiviral drugs: an update. AIDS (2005) 0.99
Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology (2009) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol (2009) 0.97
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol (2003) 0.97
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care (2011) 0.96
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst (2007) 0.96
Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease). Orphanet J Rare Dis (2011) 0.96
Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer (2011) 0.96
Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol (2013) 0.95
Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med (2004) 0.95
Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2011) 0.95
Kidney diseases in HIV/HCV-co-infected patients. AIDS (2009) 0.95
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke (2014) 0.95
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol (2006) 0.94
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS (2010) 0.93
Sunitinib malate. Cancer Chemother Pharmacol (2006) 0.92
Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: A randomised trial. Atherosclerosis (2010) 0.92
Identification of the BCAR1-CFDP1-TMEM170A locus as a determinant of carotid intima-media thickness and coronary artery disease risk. Circ Cardiovasc Genet (2012) 0.92
Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis (2003) 0.92